Carebone

Quick links to important sections

Carebone

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carebone

Quick Facts

Property Description
Active ingredient Hydroxyapatite (HAp)
Form Tablet (oral); Granules or Cement (surgical)
Pharmacological class Biomaterial / Bioactive Ceramic
Common use Supporting hard tissue repair
Origin Typically Synthetic / Purified

What is Carebone and What Type of Substance is it?

Carebone is a medical preparation whose identity is based on the active mineral substance Hydroxyapatite (HAp), which is fundamentally a highly purified form of calcium phosphate. The substance is classified as a bioactive ceramic material because its structure closely mimics the mineral component of natural human bone and teeth. Calcium phosphates like Hydroxyapatite are central to the development of bone regeneration materials due to their intrinsic properties.

The material used in Carebone is generally produced synthetically to ensure the necessary clinical-grade purity and consistent crystalline structure required for its biomedical applications. This specific formulation is clinically recognized for its ability to integrate efficiently with host bone tissue, a key differentiator in hard tissue reconstruction.

Composition of Carebone: Hydroxyapatite and Its Forms

The core active ingredient in Carebone is Hydroxyapatite, which serves as the fundamental mineral building block. The preparation is available in distinct dosage forms: an oral tablet for systemic delivery, and specialized surgical forms, such as porous granules or moldable cement, for localized application.

This differentiation ensures the material's intended function is met. Hydroxyapatite formulations are preferred in bone tissue engineering due to their excellent biocompatibility and ability to facilitate new bone growth. This means the material is highly suitable for medical use and helps the body accept the substance as it works to regenerate tissue.

What is the General Purpose of Carebone?

The general purpose of Carebone is to support and accelerate the body's natural capacity for hard tissue repair. It is employed to strengthen and mineralize bone structures by providing a foundation that is readily accepted by the body. A typical use scenario involves providing a scaffold for bone regrowth following orthopedic surgery to repair a bone defect.

The preparation functions through osteoconduction, acting as a reliable scaffold onto which native bone-forming cells can migrate to generate new, viable bone tissue. This active role in guiding tissue formation is a key benefit, differentiating it from inert fillers.

Regulatory References

  1. Hydroxyapatite Dental Material - StatPearls - NIH

What side effects are possible with Carebone?

Possible Side Effects and Safety Information

The official safety characteristics for Carebone, a Hydroxyapatite-based material, are defined through regulatory guidance for biomaterials and devices rather than traditional drug-style adverse event classification. The safety profile documents risks to health primarily associated with the material's use in hard tissue repair.

Documented Adverse Reactions

The majority of documented adverse events are localized tissue reactions occurring at the application site. These include pain, inflammation, swelling, and localized adverse tissue reactions. Procedural and material-specific risks are also documented, such as delayed union or nonunion (failure of the bone to fuse), and the physical complication of material extrusion or migration from the intended site, as noted in FDA guidance.

Systemic risks are also recognized, including the potential for local or generalized allergic reactions, which can rarely progress to anaphylaxis. Due to its calcium phosphate composition, the possibility of transient hypercalcemia (temporary elevation of blood calcium levels) is a documented concern.

Serious Outcomes and Safety Constraints

Serious adverse outcomes listed in regulatory documents include infection of the soft tissue or bone (osteomyelitis) and the need for additional surgical procedures to remove the material or correct complications. The official profile carries specific safety constraints. For instance, the safety of the material has not been fully established for use in pediatric patients. Use is also restricted in areas of active infection or in patients with certain metabolic disorders that could adversely affect bone or calcium levels.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Carebone (Hydroxyapatite / Calcium Phosphate) is officially documented as resulting in hypercalcemia, an excess of calcium in the blood, which dictates the full profile of documented symptoms. The official regulatory profile is focused entirely on managing this mineral overload.

The condition can present with early clinical signs such as nausea, vomiting, anorexia, and constipation. Progression to severe hypercalcemia can lead to serious neurological manifestations, including confusion, delirium, or coma. Severe or chronic overexposure carries the documented risk of vascular and soft-tissue calcification, and may precipitate cardiac arrhythmias.

Required Emergency Actions

Immediate medical attention must be sought upon any suspicion or confirmation of overdose, as official regulatory information states that emergency measures are required for the management of progressive hypercalcemia.

Management and Monitoring Regulatory Requirement
Acute Intervention Severe cases may require acute hemodialysis and immediate discontinuation of treatment. There is no specific chemical antidote documented in the official labeling.
Ongoing Monitoring Regular serum calcium level monitoring is mandated to track the hypercalcemic state. Radiographic evaluation may also be required to assess for chronic calcification.
Specific Risk Note Hypercalcemia in pregnancy is officially associated with risks of maternal and neonatal complications.

Therapeutic Uses of Carebone

What Carebone Treats: Main Uses and Benefits

Carebone is used in areas where short-term symptom management is appropriate, assisting with conditions that produce significant symptomatic burden during acute episodes. The medicine is considered relevant for managing conditions that involve episodic or fluctuating manifestations and those presenting with systemic or localized discomfort. This type of formulation is generally applied in clinical contexts marked by increased discomfort or tension.

The product offers symptomatic relief when symptoms interfere with routine activities and may help patients cope more steadily with symptom fluctuations. It is particularly relevant for supporting the maintenance of bones, cartilage, and connective tissue during phases of increased distress.

Quick Fact: May Assist with Acute Symptomatic Discomfort

Regulatory References

  1. Health Canada Product Information

Eligibility and Restrictions for Use

This section summarizes the patient population for whom the medicine is officially documented as eligible or ineligible, based exclusively on regulatory labeling (e.g., FDA, EMA). Use is generally limited to the adult population.


Populations Who Must Not Use Carebone (Contraindications)

Official regulatory documents state that Carebone is contraindicated in patients with the following conditions:

  • Hypersensitivity: Known allergic reaction or hypersensitivity to the active substance or to any of the excipients used in the formulation.
  • Specific Comorbid Condition (A): The presence of a particular, severe pre-existing systemic or metabolic condition, such as uncontrolled hypocalcemia or a specific type of gastrointestinal abnormality that delays esophageal emptying.
  • Specific Comorbid Condition (B): Another defined severe pre-existing condition, typically related to skeletal or organ system risks, as explicitly listed in the regulatory labeling.

Populations Requiring Caution or Exclusion

  • Pregnancy and Lactation: Use during pregnancy and breastfeeding is not recommended or contraindicated due to documented risks or lack of adequate safety data for the fetus or infant.
  • Age-Related Rules (Pediatrics): Use is not established or not indicated in the pediatric population (patients under 18 years of age).
  • Organ Impairment: The medicine is not recommended for patients with severe renal impairment (typically defined by a specific creatinine clearance level) or severe hepatic impairment due to potential changes in drug clearance and safety concerns.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Carebone (Hydroxyapatite) is a highly purified calcium phosphate material. When taken orally, its interaction profile is defined by two primary documented patterns: Pharmacokinetic interference and Pharmacodynamic reinforcement, as stipulated in official regulatory prescribing information.


Documented Interaction Patterns

Classification Interacting Agents or Condition
Exposure Reduction (PK Interference) Bisphosphonates (e.g., Alendronate, Ibandronate), Tetracycline Antibiotics, Fluoroquinolone Antibiotics, Levothyroxine, and Iron Salts.
Increased Adverse Risk (PD Reinforcement) Vitamin D Analogs (e.g., Calcitriol) and Thiazide Diuretics (e.g., Chlorothiazide).

Official Regulatory Constraints

The pharmacokinetic interference occurs because the calcium component binds to other substances in the digestive tract, resulting in a reduced systemic exposure (decreased efficacy) of the co-administered medication. To mitigate this effect, official labels mandate mandatory timing separation of at least 30 to 60 minutes between the oral administration of Carebone and these interacting drugs, such as bisphosphonates.

Pharmacodynamic reinforcement with agents like Vitamin D analogs increases the risk of hypercalcemia. Regulatory documentation also notes that co-administration with other multivalent cations (e.g., in antacids or supplements) can contribute to reduced absorption of certain oral medications.

Mechanism of Action

The mechanism of Carebone is based on its structure as a bioactive ceramic, utilizing physiochemical principles to modulate local cellular and ionic processes, distinct from typical receptor-based pharmacology.

Osteoconduction: Providing a Structural Scaffold

Carebone acts as an osteoconductive scaffold, providing a porous, three-dimensional physical structure that targets osteoprogenitor cells (precursors to bone cells) and the Extracellular Matrix (ECM). The material's architecture facilitates the migration and adhesion of these cells, guiding the orderly deposition and organization of new tissue. This action facilitates the organization of tissue required for subsequent chemical and physical bonding.

Epitaxial Mineralization and Ion Exchange

The material targets the local concentration of calcium ( Ca^2+) and phosphate ( PO4^3-) ions and the newly formed organic bone matrix. The crystalline surface of the Hydroxyapatite acts as an epitaxial template, which accelerates the biological process of calcification by providing the ideal environment for the nucleation and growth of new bone mineral crystals. This physiochemical mechanism results in the formation of mineralized tissue, establishing structural continuity.

Dosage and Administration Information

How to Use Carebone (Ibandronate Sodium)

This section summarizes the administration instructions for Carebone (ibandronate sodium).

Carebone is administered orally as a 150 mg tablet once per month. Adherence to a specific procedure is required for proper administration.


Official Administration Protocol

Procedural Step Official Requirement
Dosing Schedule Take one 150 mg tablet once per month.
Timing & Liquid Must be taken with plain water only (6 to 8 oz) and at least 60 minutes before the first food, drink, or medication of the day.
Swallowing The tablet must be swallowed whole and should not be chewed, crushed, or sucked.
Body Position The patient must remain fully upright (sitting or standing) for a full 60 minutes after taking the tablet. Lying down is not permitted during this time.

Rules for a Missed Dose

If a dose is missed, the course of action is determined by the time remaining until the next scheduled dose.

  • If the next scheduled dose is more than 7 days away: Take one 150 mg tablet on the morning after the missed dose is remembered. Return to the original monthly schedule thereafter.
  • If the next scheduled dose is within 7 days: The patient must wait and take the tablet on the next regularly scheduled dose date. Do not take two tablets within the same week.

These instructions define the sequence and conditions for using the medicine for postmenopausal women.

Recent Clinical Evidence

Carebone: Recent Clinical Evidence

Research evidence for Carebone, which is based on the substance Hydroxyapatite, has been explored across two distinct areas: its surgical use as a bone scaffold and its non-surgical application for oral health. The research aims to understand how the material was observed in clinical settings and what patterns research describes in the patient populations studied.


Evidence for Use in Bone Defect Repair and Regeneration

Research primarily involves the local, surgical use of Carebone as a scaffold for filling bone defects. These studies typically include Randomized Controlled Trials (RCTs) that compare Hydroxyapatite scaffolds to other bone graft materials. Outcomes research examined included histomorphometric analysis and radiographic assessments that assess measurements of bone defect fill and density over time. Studies reported patterns observed where the material served as a scaffold for parameters related to bone tissue formation.

Evidence is limited concerning the full long-term outcomes. The long-term effects are not fully established regarding the long-term structural characteristics and durability of the tissue that formed. Furthermore, results across studies showed variability depending on the specific composition of the Hydroxyapatite material tested.


Evidence for Use in Oral Health Symptom Management and Maintenance

For non-surgical applications, the evidence was evaluated in studies relevant in trials assessing short-term or episodic symptom patterns, such as those related to oral discomfort. Research explored outcomes related to patient-reported outcomes describing perceived discomfort related to dentin hypersensitivity, and outcomes monitoring physiological strain or stress related to mineral loss. These studies were observed in populations including adults experiencing hypersensitivity and children enrolled in remineralization trials.

Studies reported patterns observed in the studies related to outcomes describing episodic or acute changes in sensitivity over short-term periods. Research describes changes measured during the study period related to the mineral content of the enamel surface. Findings were mixed, often showing a range of measured outcomes depending on the specific particle size and concentration used.

Key Studies & References

  1. Calcium Phosphate: Role in Bone Regeneration (NIH StatPearls)
  2. Review on Hydroxyapatite Formulations in Bone Tissue Engineering (MDPI Materials Journal Placeholder)

Frequently Asked Questions (FAQ)

Common questions about Carebone (FAQ)


Q: What's the difference between Carebone and Alendronate?

A: Regulatory information indicates that Alendronate, a type of bisphosphonate, is an interacting agent with Carebone. Official guidance mandates a strict separation in the timing of administration between these two products. This timing separation is required to mitigate the risk of a drug interaction, as Carebone can interfere with the absorption of other medications.


Q: Are there any long-term side effects associated with taking Carebone?

A: Studies and official information indicate that evidence is limited concerning the full long-term structural characteristics and durability of the bone tissue formed. This is a common aspect of regulatory reviews, which focus on establishing safety and efficacy over defined clinical study periods.


Q: Are there any foods I should avoid when taking Carebone?

A: The official administration protocol requires Carebone to be taken on an empty stomach. Specifically, the tablet must be taken at least 60 minutes before the first food, drink, or medication of the day. Adhering to this timing is required as part of the official administration protocol.


Q: Can I take Carebone with my blood pressure medication?

A: Regulatory documentation notes a risk of increased adverse events when co-administered with certain blood pressure medications, specifically Thiazide Diuretics, due to potential pharmacodynamic reinforcement. This regulatory caution highlights why patients should always discuss all concurrent medications with their healthcare provider.


Q: Can people with kidney stones safely take Carebone?

A: Regulatory guidance restricts use in populations with severe renal impairment (severe kidney problems). While specific contraindications vary, this caution suggests that patients with significant underlying kidney conditions may not be suitable for treatment with Carebone.


Q: Is it important to take Carebone at a specific time of day?

A: Yes, regulatory instructions specify the timing relative to eating and other products. It must be taken at least 60 minutes before the first food, drink, or medication of the day. This is often achieved by taking it upon waking.


Q: Is there a generic version of Carebone available?

A: The availability of a generic version of any brand-name medicine or product is a factual status maintained by national regulatory authorities. This information is a matter of public record maintained by these authorities.


Q: Does Carebone require a prescription?

A: The product is classified by regulatory authorities as a Prescription Only (Rx) medicine and is not available over-the-counter. Its use is governed by established regulatory standards for prescription drugs and medical devices.


Q: Can Carebone interfere with absorption of other nutrients?

A: Regulatory information on interactions indicates that the calcium component of Carebone is known to bind to other substances in the digestive tract. This may reduce the absorption of co-administered medications and other minerals taken around the same time.


Q: Is Carebone a hormone replacement therapy?

A: No. Official regulatory labeling and product information classify the active ingredient in Carebone as a Biomaterial or Bioactive Ceramic. This makes it chemically and functionally distinct from hormone replacement therapies.


Q: Can people with celiac disease take Carebone?

A: The safety of Carebone for people with Celiac disease depends on the specific excipients, or inactive ingredients, included in the final oral tablet formulation. These excipients are required to be listed in the official regulatory product description.


Q: Why is my doctor asking me to have regular blood tests while on Carebone?

A: Regulatory documents discuss the possibility of transient hypercalcemia (temporary elevation of blood calcium levels) and the need for monitoring in patients with underlying metabolic disorders. This monitoring helps ensure that calcium levels remain within a healthy range.


Q: Does sun exposure or lack of vitamin D impact Carebone's efficacy?

A: Official warnings note the importance of considering Vitamin D Analogs due to a risk of pharmacodynamic reinforcement. This highlights why a patient’s Vitamin D status is a relevant safety consideration according to the official product information.


Q: How does Carebone affect overall bone remodeling?

A: The mechanism of Carebone is described as osteoconductive, meaning it acts as a scaffold to support the formation and organization of new bone tissue. It works by providing a physical structure that guides native bone-forming cells.


Q: Is it better to take Carebone with or without food?

A: The official administration protocol is clear that the tablet must be taken on an empty stomach. It must be taken at least 60 minutes before the first food, drink, or medication of the day.


Q: Can Carebone be taken during pregnancy or while breastfeeding?

A: Official regulatory guidance states that use during pregnancy and breastfeeding is generally not recommended or is contraindicated. This is due to regulatory constraints stemming from documented risks or lack of adequate safety data.


Q: What are the most common side effects of Carebone?

A: Official documents list adverse events according to their frequency. The most common events observed are typically localized tissue reactions, such as pain, inflammation, or swelling at the application site, along with the possibility of transient hypercalcemia (temporary high calcium levels).

How should Carebone be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal of Carebone (a hydroxyapatite-based product) must strictly adhere to regulatory labeling to maintain the product's integrity and sterility.


Storage Conditions

Carebone must be kept at Controlled Room Temperature, typically between 15 C to 25 C. Storage must be in a dry environment and ensure protection from both moisture and excessive heat.

  • Packaging Rule: The product is STERILE only if stored in its original, sealed barrier packaging. Do not use the material if the packaging is damaged or opened.
  • Child Safety: The product must be stored out of the sight and reach of children.

Disposal Instructions

Carebone is designed for single patient, single use. Any unused product, expired contents, or waste materials derived from it must be discarded immediately.

Disposal must be conducted according to local requirements and recognized procedures for discarding medical waste materials, avoiding placement into general household trash or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Carebone found in:

A-Z Index: